At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Office of Human Research, Taipei Medical University
In Brief
A clinical study evaluating Glucomannan noodle and Placebo noodle for Metabolic Syndrome. Completed, enrolled 36 participants.
Detailed Summary
Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat concentration, and weight management, and has other health benefits.The purposes of this study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and diabetic patients.
Study Details
Timeline
Interventions
The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.